Drugs / CD19/CD22-BBz
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05507827 | Aug 2022 → Jun 2025 overdue | lymphoid leukemia | Stanford University | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/CD22-BBz | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05507827 ↗ |
| Modality | Cell therapy | “Newer CAR T cells targeting CD22 or the combination of CD19 and CD22 are being studied to address the issue of antigen escape.” PMID 41671463 ↗ Dec 2025 |
| Route | Intravenous | “via IV administration” NCT05507827 ↗ |
| Target | CD19 | “Newer CAR T cells targeting CD22 or the combination of CD19 and CD22 are being studied to address the issue of antigen escape.” PMID 41671463 ↗ Dec 2025 |
| Target | CD22 | “Newer CAR T cells targeting CD22 or the combination of CD19 and CD22 are being studied to address the issue of antigen escape.” PMID 41671463 ↗ Dec 2025 |